ANI PHARMACEUTICALS, INC Interest Income, Deposits with Financial Institutions
ANI PHARMACEUTICALS, INC (ANIP) reported Interest Income, Deposits with Financial Institutions of $2.64 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeDepositsWithFinancialInstitutions · last filed 2026-08-07
- ANI PHARMACEUTICALS, INC interest income, deposits with financial institutions for the quarter ending 2026-06-30 was $2.64M, a 80.80% increase year-over-year.
- ANI PHARMACEUTICALS, INC interest income, deposits with financial institutions for the quarter ending 2026-03-31 was $2.64M, a 99.77% increase year-over-year.
- ANI PHARMACEUTICALS, INC interest income, deposits with financial institutions for the quarter ending 2025-12-31 was $2.29M, a 75.08% increase year-over-year.
- ANI PHARMACEUTICALS, INC interest income, deposits with financial institutions for the quarter ending 2025-09-30 was $2.18M, a 14.07% decline year-over-year.
- ANI PHARMACEUTICALS, INC interest income, deposits with financial institutions for fiscal 2025 was $7.25M, a 21.81% decline from fiscal 2024.
- ANI PHARMACEUTICALS, INC interest income, deposits with financial institutions for fiscal 2024 was $9.27M, a 67.66% increase from fiscal 2023.
- ANI PHARMACEUTICALS, INC interest income, deposits with financial institutions for fiscal 2023 was $5.53M, a 1410.38% increase from fiscal 2022.
- ANI PHARMACEUTICALS, INC interest income, deposits with financial institutions for fiscal 2022 was $366.00K.
| Period end | Interest Income, Deposits with Financial Institutions 3 month | Interest Income, Deposits with Financial Institutions 6 month | Interest Income, Deposits with Financial Institutions 9 month | Interest Income, Deposits with Financial Institutions 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.64M 10-Q · filed 2026-08-07 | $5.27M 10-Q · filed 2026-08-07 | $7.56M derived: sum of 3 quarters · filed 2026-08-07 | $9.74M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $2.64M 10-Q · filed 2026-05-08 | $4.93M derived: sum of 2 quarters · filed 2026-05-08 | $7.11M derived: sum of 3 quarters · filed 2026-05-08 | $8.56M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $2.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $4.47M derived: sum of 2 quarters · filed 2026-02-27 | $5.93M derived: sum of 3 quarters · filed 2026-08-07 | $7.25M 10-K · filed 2026-02-27 |
| 2025-09-30 | $2.18M 10-Q · filed 2025-11-07 | $3.64M derived: sum of 2 quarters · filed 2026-08-07 | $4.96M 10-Q · filed 2025-11-07 | $6.27M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $1.46M 10-Q · filed 2026-08-07 | $2.78M 10-Q · filed 2026-08-07 | $4.09M derived: sum of 3 quarters · filed 2026-08-07 | $6.62M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $1.32M 10-Q · filed 2026-05-08 | $2.63M derived: sum of 2 quarters · filed 2026-05-08 | $5.17M derived: sum of 3 quarters · filed 2026-05-08 | $7.80M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $3.85M derived: sum of 2 quarters · filed 2026-02-27 | $6.48M derived: sum of 3 quarters · filed 2026-02-27 | $9.27M 10-K · filed 2026-02-27 |
| 2024-09-30 | $2.54M 10-Q · filed 2025-11-07 | $5.17M derived: sum of 2 quarters · filed 2025-11-07 | $7.96M 10-Q · filed 2025-11-07 | |
| 2024-06-30 | $2.63M 10-Q · filed 2025-08-08 | $5.42M 10-Q · filed 2025-08-08 | ||
| 2024-03-31 | $2.79M 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | $5.53M 10-K · filed 2026-02-27 | |||
| 2022-12-31 | $366.00K 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |